Clinical Observation on the Effect of Zengse Pill （增色丸） in Treating Patients with Vitiligo of Qi-stagnancy and Blood-stasis Syndrome Type

Objective： To observe the clinical efficacy of Zengse Pill （增色丸, ZSP） on patients with vitiligo of qi-stagnancy and blood-stasis syndrome type （V-QB）, and to preliminarily explore its mechanism of action. Methods： Sixty-five V-QB patients, with their diagnosis confirmed by clinical examination, were randomized by digital table method into two groups, with 31 patients in the control group and 34 in the treatment group. Cobamamide （2 tablets） was administered orally to all patients, and Psoralea tincture （a self-formulated preparation） was applied externally thrice a day. In addition, for patients in the treatment group, ZSP was given orally, at 5 pills per dose, 3 times every day. The therapeutic course for both groups was 3 months. Patients were re-examined every half-month, and changes in the skin lesions were observed and recorded. The levels of lymphocyte subsets, serum immune globulin, and complement C3 and C4 in patients were determined before and after the therapeutic course and compared with the corresponding indexes determined in 21 healthy subjects, Results： The total effective rate in the treatment group was 82.4%, which was markedly higher than that in the control group （54.8%）, showing a significant difference （P〈O.05）. After treatment, CD4^＋ percentage, CD4^＋/CD8^＋ratio, and blood levels of C3 and C4 increased, while CD8^＋ percentage decreased in the treatment group （P〈0.05 or P〈0.01）. All these indexes remained unchanged in the control group, and the respective comparisons between groups showed significant differences （P〈0.01）. Conclusion： ZSP has a definite clinical effect on the treatment of V-QB but with no evident adverse reactions, and it can increase the CD4^＋ percentage, CD4^＋/CD8^＋ ratio, and the levels of serum C3 and C4, thus regulating the immunity of the organism, which might be one of its mechanisms of action.     

白癜风动物模型制备规范(草案)

白癜风是一种获得性色素脱失皮肤病,发病率0.5%~1%[1]。发病人群以年轻人偏多,易诊难治,影响美观[2]。目前白癜风的发病机制尚不明确,可能与遗传因素、自身免疫、精神创伤、神经化学因子、黑素细胞自身破坏等因素有关。现白癜风动物模型为病理性动物模型,以西医指标为主。基于对白癜风中西医临床病症特点分析及对现有动物模型大量实验研究,形成如下白癜风动物模型制备规范(草案),以期为该模型的相关研究提供参考。     

Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity

Although antibodies (Abs) produced by B cells can treat cancer in certain models, T cells have been accountable for the major effector to control cancer. Immune recognition toward tyrosinase-related protein-1 (TRP-1), a melanoma associated antigen up-regulated on the surface of B16F10 melanomas, generally leads to tumor protection mediated by Abs. In this study, immunization with dendritic cells ex vivo transduced with adenovirus encoding TRP-1 stimulates immune activation and potent tumor protection mediated by CD8 T cells in the absence of autoimmune consequence. Transfer of CD8 T cells from immunized mice also leads to tumor protection. The immune activation and CD8 T cell mediated tumor protection rely on the CD4 T cell help. Thus DC based genetic immunization targeting TRP-1, an antigen usually causes Ab predominant immune recognition, is capable of stimulating potent tumor protection dependent on CD8 T cells in the absence of autoimmunity.     

308nm准分子激光联合胸腺肽治疗成人头面部白癜风临床观察

目的:探讨口服胸腺肽联合308nm准分子激光治疗白癜风的疗效及安全性。方法:85例患者随机分成两组。实验组44例,308nm准分子激光(2次/周)联合胸腺肽(10mg 2/日)治疗;对照组41例,单纯予308nm准分子激光治疗(2次/周),两组疗程25次。于治疗25次3天后进行疗效评价。结果:治疗结束后,实验组有效率为95.45%(42/44),对照组为87.8%(36/41),显效率实验组为72.73%(32/44),对照组为51.22%(21/41),两组间显效率有显著性差异(χ2=4.182,P=0.041),但有效率差异不显著(χ2=3.316,P=0.375)。对两组各30例患者随访6个月,实验组患者所有治疗皮损均维持稳定或持续好转,而对照组有2例皮损出现复发。结论:308nm准分子激光治疗白癜风疗效高、副作用少,联合口服胸腺肽可显著提高其疗效并减少复发。     

自体黑素细胞体外培养与移植治疗白癜风的研究

[目的]研究和探索黑素细胞培养移植治疗白癜风的方法与疗效.[方法]采用从发疱壁上获取黑素细胞、纯黑素细胞培养与增殖、移植区刮除种植法,进行自体黑素细胞培养移植治疗白癜风.[结果]18例白癜风患者中21块皮损进行了自体黑素细胞培养移植,总有效率为90.48%.[结论]此操作方法较简单、治疗面积大,色素分部均匀,值得临床推广和应用.     

Therapeutic options and hot topics in vitiligo with special focus on pediatrics' vitiligo: A comprehensive review study

Vitiligo is a common skin disorder with an estimated worldwide prevalence to 2.28% which is connected with selective melanocytes loss which leads to depigmentation and chalky‐white macules. Vitiligo may be dismissed as a cosmetic problem and may have psychologic impacts on patients. It is occurring in both children and adults and is considered as the most common depigmenting skin disorder in the world. There are still many unknown topics about this disease regarding to its treatment in pediatrics, curable drugs and manifestations. Therefore, we decided to evaluate the recent studies about its therapeutic strategies in pediatrics. Topical therapies should be considered as first line treatment in children, but phototherapy especially NBUVB may be used after topical treatment modalities failure or in extensive or rapidly progressive disease. Our suggestion for the treatment of this disease in children is to use combine treatment modalities with observing safety according to the patient's age.     

Evaluation of the potential interference of camouflage on the treatment of vitiligo: An observer‐blinded self‐controlled study

Camouflage improves the quality of life in vitiligo patients. However, whether the use of camouflage interferes the efficacy of the treatment of vitiligo remains controversial. To evaluate the impact and safety of dihydroxyacetone (DHA)‐containing camouflage on the treatment of vitiligo. Thirty patients were enrolled. Comparable vitiliginous patches in each patient were randomly divided into camouflage group or blank group. The therapeutic modalities including topical corticosteroids with or without NB‐UVB phototherapy were applied to both groups of lesions. The outcomes were assessed at baseline and then every 4 weeks for up to 12 weeks, including types of repigmentation patterns, percentage of repigmentation, trans epidermal water loss (TEWL), and adverse events. Twenty‐eight patients completed the study. There were no differences in repigmentation types and percentage of repigmentation at the endpoint of study between two groups. No difference in TEWL was found at the end of the study between the two groups. Temporary skin irritation (itching and tingling) occurred in one patient in camouflage group after phototherapy between 8 and 12 weeks' treatment. DHA‐containing camouflage is a safe make‐up for vitiligo. It has little impact on the efficacy of the treatment of vitiligo or on the function of skin barrier.     

他克莫司软膏联合308 nm准分子激光治疗白癜风临床疗效观察

目的：评价0．1％和0．03％他克莫司软膏联合308nm准分子激光治疗对紫外线治疗抵抗的白癜风皮损的疗效与安全性。方法：采用随机、自身对照的临床试验，每例患者选取紫外线治疗抵抗区域的皮损，随机选取躯体一侧皮损为治疗侧，采用他克莫司软膏联合308nm准分子激光治疗；另一侧为对照侧，仅用308nm准分子激光治疗。2个月后进行疗效判定。结果：联合治疗组有效率为89．0％，对照组为71．6％，两组间疗效比较差异有统计学意义（P〈0．05）。结论：他克莫司软膏联合308nm准分子激光治疗白癜风起效快，疗效好。